SPHERA FUNDS MANAGEMENT LTD. - Q2 2013 holdings

Add to watchlist

All
New
Buy
Sell
Exit
Unchanged
 Value Shares↓ Weighting
No holdings reported for quarter Q2 2013
Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
TEVA PHARMACEUTICAL-SP ADR36Q3 20238.4%
MERCK & CO INC NEW35Q3 20238.4%
NICE Systems Ltd27Q3 20234.4%
BIOGEN INC26Q3 20236.7%
AMICUS THERAPEUTICS INC26Q2 20224.3%
PFIZER INC25Q3 20239.2%
SAREPTA THERAPEUTICS INC25Q3 20233.2%
JOHNSON & JOHNSON24Q3 20238.0%
UNIQURE NV23Q3 20231.2%
SYNDAX PHARMACEUTICALS INC22Q3 20233.9%

View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.

Latest significant ownerships (13-D/G)
SPHERA FUNDS MANAGEMENT LTD. Q2 2013 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Cyclacel Pharmaceuticals, Inc.February 06, 2023250,0002.0%
Altimmune, Inc.February 14, 20221,244,2413.1%
Allot Ltd.February 16, 20211,129,0543.2%
Larimar Therapeutics, Inc.February 16, 2021? ?
Neos Therapeutics, Inc.February 16, 2021? ?
Orgenesis Inc.February 16, 2021525,2160.0%
Sio Gene Therapies Inc.February 16, 2021? ?
X4 Pharmaceuticals, IncFebruary 16, 2021250,0000.0%
Axovant Gene Therapies Ltd.February 25, 20202,931,0178.0%
Axovant Gene Therapies Ltd.February 11, 2020398,5401.8%

View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.

Latest filings
TypeFiled
13F-HR/A2024-02-15
13F-HR2024-02-14
SC 13G2024-02-08
SC 13G/A2024-02-05
SC 13G/A2024-02-05
SC 13G/A2024-02-05
SC 13G/A2024-02-05
13F-HR2023-11-14
SC 13G2023-10-10
SC 13G2023-08-30

View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.

All filings

View complete filings history.

Compare quarters

Export SPHERA FUNDS MANAGEMENT LTD.'s holdings

CSVXLS